Wednesday, June 10, 2026

Patent intelligence · WO

WO 2025256977

NOUVELLES ENZYMES DE CLIVAGE IGM ET IGG

granted A61K 38/ 48 A IA61P 37/ 06 A IA61P 43/ 00 A IA61P/3706
Status granted
Years to expiry 20
Applicant portfolio 25
Patent details — WO 2025256977
Jurisdiction
WO
Status
granted
Grant date
Dec 18, 2025
Expiration
Dec 13, 2045
Applicant
BAYER AG [DE]
CPC classes
A61K 38/ 48 A I, A61P 37/ 06 A I, A61P 43/ 00 A I, A61P/3706
View on Google Patents ↗

Quick answer

WO 2025256977 (NOUVELLES ENZYMES DE CLIVAGE IGM ET IGG) is held by BAYER AG [DE]. Status: granted. Granted Dec 18, 2025. Expires Dec 13, 2045 (20 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Applicant
BAYER AG [DE]
Grant date
Expiration
Claims
CPC classes
A61K 38/ 48 A I, A61P 37/ 06 A I, A61P 43/ 00 A I, A61P/3706, A61P/4300

More from BAYER AG [DE]

Related pharmaceutical patents in our USPTO index.

  1. WO 2026112109

    TECHNOLOGIE DE PLATEFORME DE GRANULATION PAR VOIE HUMIDE POUR FABRIQUER DES COMPRIMÉS/ARTICLES À MÂCHER MOUS

    BAYER HEALTHCARE LLC [US] · Expires May 23, 2046

    granted
  2. WO 2026106858

    FORMULATIONS ET PROCÉDÉS POUR MAINTENIR UNE SUSPENSION ET UNE VIABILITÉ DE CELLULES

    BAYER HEALTHCARE LLC [US] · Expires May 16, 2046

    granted
  3. EP 4741400

    MULTIMERE MANGANKONTRASTMITTEL

    BAYER AG [DE] · Expires May 8, 2046

    granted
  4. WO 2026068294

    PROCESSUS DE NANOENSEMENCEMENT AMÉLIORÉ

    BAYER AG [DE] · Expires Mar 28, 2046

    granted
  5. WO 2026047020

    FORMES CRISTALLINES D'INHIBITEURS DE HER2/MUTEGFR ET LEUR PROCÉDÉ DE PRÉPARATION

    BAYER AG [DE] · Expires Feb 28, 2046

    granted
  6. WO 2026047022

    FORME POSOLOGIQUE PHARMACEUTIQUE SOLIDE ET STABLE COMPRENANT UNE FORME CRISTALLINE D'UN INHIBITEUR DE HER2/MUTEGFR ET SA MÉTHODE DE PRÉPARATION

    BAYER AG [DE] · Expires Feb 28, 2046

    granted
  7. US 20260051027

    GENERATION OF SYNTHETIC CONTRAST-ENHANCED RADIOLOGICAL IMAGES

    BAYER AG [DE] · Expires Feb 14, 2046

    granted
  8. WO 2026032865

    SEL D'UN INHIBITEUR DE SOS-1

    BAYER AG [DE] · Expires Feb 7, 2046

    granted

Frequently asked questions

What is US patent 2025256977?

WO 2025256977 (NOUVELLES ENZYMES DE CLIVAGE IGM ET IGG) is held by BAYER AG [DE]. Status: granted. Granted Dec 18, 2025. Expires Dec 13, 2045 (20 years remaining) — relevant for patent-cliff and LOE planning.

Who owns WO 2025256977?

BAYER AG [DE] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 25 pharmaceutical patents for this assignee.

When does WO 2025256977 expire?

Our index shows an expiration date of Dec 13, 2045 (20 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.